Outlook Therapeutics, Inc.
-
Ticker
OTLK
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 11-50 Employees
- Based in Cranbury, New Jersey
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation
…More of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
REPORT RATINGS
4.7 / 5.0 (115)
Outlook Therapeutics, Inc. reports have an aggregate usefulness score of 4.7 based on 115 reviews.
Outlook Therapeutics, Inc.
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
Older/Archived Annual Reports